HEPION PHARMACEUTICALS INC (HEPA)
US4268973025 - Common Stock
Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference
EDISON, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on...
Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer
- Research study demonstrates regulation of chromatin structure and cancer gene expression – - Findings to augment clinical trial in liver cancer - ...
Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosis
– Proteomics analysis showed that rencofilstat improved aberrant protein profiles in IPF tissues – – Superior effects of rencofilstat alone and...
Hepion Pharmaceuticals Announces Management Changes
EDISON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on...
Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023
- Preclinical studies demonstrate rencofilstat may protect against NASH/NAFLD, shift the liver transcriptome and lipidome toward NASH resolution – -...
Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of Rencofilstat
Completion of Enrollment Remains on Track for Q1, 2024...
Hepion Pharmaceuticals to Highlight AI-POWR™ at the 2023 CSPS Annual Symposium: The Next Frontiers in Pharmaceutical Sciences
EDISON, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to keep an eye on Tuesday!
Why is Mallinckrodt (MNK) Stock Down 27% Today?
Mallinckrodt (MNK) stock is falling on Monday with strong trading despite a lack of news concerning the pharmaceutical company.
Why Is Volcon (VLCN) Stock Down 37% Today?
Volcon (VLCN) stock is taking a beating on Monday after the all-electric powersports company announced a public equity offering.
Why Is SeqLL (SQL) Stock Up 43% Today?
SeqLL (SQL) stock is on the rise Monday with heavy trading despite a lack of news from the molecule sequencing technology company.
Why Is Hepion Pharmaceuticals (HEPA) Stock Up 68% Today?
Hepion Pharmaceuticals (HEPA) stock is rising higher on Monday as the company prepares to cover clinical trial results this morning.
Hepion Pharma NASH candidate meets phase 2 goal; up 68% (NASDAQ:HEPA)
Hepion Pharmaceuticals (HEPA) non-alcoholic steatohepatitis (NASH) candidate rencofilstat met primary and secondary endpoints in a mid-stage trial. Read more here.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about on Monday!
Hepion Pharmaceuticals’ Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers
- Improvements in physiologic liver function and key NASH biomarkers including ALT, ProC3, PIIINP and ELF - - Results reinforce rencofilstat’s direct...
Hepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat
EDISON, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on...
Hepion Pharmaceuticals, Inc. Announces Reverse Stock Split
EDISON, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on...
Hepion Pharmaceuticals to Present Data on Synergistic Effects of Rencofilstat with Anti-PD1 at AACR 2023
EDISON, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on...
Hepion Pharmaceuticals Expands SAB with Appointments of Four Liver Disease KOLs
EDISON, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on...
Hepion Pharmaceuticals to Participate in ACS-JPS Webinar on AI Drug Development
EDISON, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on...
Hepion Pharmaceuticals to Deliver Updates on Ongoing Phase 2 NASH Clinical Program with Rencofilstat at 6th Global NASH Congress
EDISON, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on...
EPO Decision to Grant European Patent for Rencofilstat Further Strengthens Hepion’s Patent Portfolio
– Patent Covers 38 European Countries – – Rencofilstat’s Exclusivity May Extend into 2048 – EDISON, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- Hepion...
Hepion Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell on February 10, 2023
EDISON, N.J., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on...